Cardiovascular changes in spontaneously hypertensive rats are improved by chronic treatment with zofenopril

British Journal of Pharmacology

Volumn 158, Issue 8, 2009, Pages 1911-1921

  Gomez Roso M ^a   Montero, Mj ^a   Carron R ^a   Sevilla, Ma ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Angiotensin converting enzyme; Hypertension; Remodelling; Superoxide anion; Vascular reactivity; Zofenopril

Indexed keywords

ACETYLCHOLINE; DIPEPTIDYL CARBOXYPEPTIDASE; LUCIGENIN; N(G) NITROARGININE METHYL ESTER; NITROPRUSSIDE SODIUM; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE; ZOFENOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; BODY WEIGHT; CARDIOVASCULAR EFFECT; CHEMOLUMINESCENCE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME INHIBITION; FLUOROMETRY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; KIDNEY HYPERTROPHY; LONG TERM CARE; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; TREATMENT DURATION; VASCULAR ENDOTHELIUM; VASCULAR RING; VASODILATATION; WISTAR KYOTO RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BLOOD PRESSURE; CAPTOPRIL; CARDIOMEGALY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FLUOROMETRY; HYPERTENSION; MALE; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 71649092756     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00491.x     Document Type: Article

References (55)

1. Adeagbo AS, Zhang X, Patel D, Joshua IG, Wang Y, Sun X et al. (2005). Cyclo-oxygenase-2, endothelium and aortic reactivity during deoxycorticosterone acetate salt-induced hypertension. J Hypertens 23: 1025 1036.
2. Agabiti-Rosei E, Muiesan ML, Salvetti M (2007). New approaches to the assessment of left ventricular hypertrophy. Ther Adv Cardiovasc Dis 1: 119 128.
3. rd edition. Br J Pharmacol. 153 (Suppl. 2 S1 209.
4. Alvarez Y, Briones AM, Balfagón G, Alonso MJ, Salaices M (2005). Hypertension increases the participation of vasoconstrictor prostanoids from cyclooxygenase-2 in phenylephrine responses. J Hypertens 23: 767 777.
5. Ambrosioni E, Borghi C, Magnani B (1995). The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 332: 80 85.
6. Bhoola KD, Figueroa CD, Worthy K (1992). Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44: 1 80.
7. Borghi C, Ambrosioni E, Magnani B (1996). Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. The SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Cardiol 78: 317 322.
8. Borghi C, Bacchelli S, Esposti DD, Bignamini A, Magnani B, Ambrosioni E (1999). Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Hypertens 12: 665 672.
9. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye-binding. Anal Biochem 72: 248 254.
10. Buczko W, Kramkowski K, Mogielnicki A (2006). Are the endothelial mechanisms of ACE-Is already established? Pharmacol Rep 58: 126 131.
11. Buikema H, Monnink SH, Tio RA, Crijns HJ, de Zeeuw D, van Gilst WH (2000). Comparison of Zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 130: 1999 2007.
12. Cai H, Harrison DG (2000). Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87: 840 844.
13. Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE, McMurray J (1992). Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl-and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol 19: 330 340.
14. Cominacini L, Pasini A, Garbin U, Evangelista S, Crea AE, Tagliacozzi D et al. (2002). Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 15: 891 895.
15. Danser AH (1996). Local renin-angiotensin systems. Mol Cel Biochem 157: 211 216.
16. Erdös EG (1976). Conversion of angiotensin I to angiotensin II. Am J Med 60: 749 759.
17. Evangelista S, Manzini S (2005). Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 33: 42 54.
18. Friedland J, Silverstein M (1976). A sensitive fluorimetric assay for serum angiotensin-converting enzyme. Am J Clin Pathol 66: 416 424.
19. Gagnon C, Legault F, Geraldes P, Tanguay JF, Lambert C (2004). Diverse effects of Ace inhibitors and angiotensin II receptor antagonists on prevention of cardiac hypertrophy and collagen distribution in spontaneously hypertensive rats. Int J Cardiol 97: 373 381.
20. Galderisi M, de Divitiis O (2008). Risk factor-induced cardiovascular remodelling and the effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 51: 523 531.
21. Garcia-Cohen EC, Marin J, Diez-Picazo LD, Baena AB, Salaices M, Rodriguez-Martinez MA (2000). Oxidative stress induced by tert-butyl hydroperoxide causes vasoconstriction in the aorta from hypertensive and aged rats: role of cyclooxygenase-2 isoform. J Pharmacol Exp Ther 293: 75 81.
22. Hayakawa H, Hirata Y, Suzuki E, Sugimoto T, Matsuoka H, Kikuchi K et al. (1993). Mechanisms for altered endothelium-dependent vasorelaxation in isolated kidneys from experimental hypertensive rats. Am J Physiol 264: H1535 H1541.
23. Heran BS, Wong MM, Heran IK, Wright JM (2008). Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev 4: 1 358.
24. Izzard AS, Rizzoni D, Agabiti-Rosei E, Heagerty AM (2005). Small artery structure and hypertension: adaptive changes and target organ damage. J Hypertens 23: 247 250.
25. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA (1999). Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension 33: 1353 1358.
26. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM (1991). Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 84: 1589 1596.
27. Lerman LO, Nath KA, Rodriguez-Porcel M, Krier JD, Schwartz RS, Napoli C et al. (2001). Increased oxidative stress in experimental renovascular hypertension. Hypertension 37: 541 546.
28. Linz W, Wiemer G, Schaper J, Zimmermann R, Nagasawa K, Gohlke P et al. (1995). Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Mol Cell Biochem 147: 89 97.
29. Liu YH, You Y, Song T, Wu SJ, Liu LY (2007). Impairment of endothelium-dependent relaxation of rat aortas by homocysteine thiolactone and attenuation by captopril. J Cardiovasc Pharmacol 50: 155 161.
30. Lüscher TF, Vanhoutte PM (1986). Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 8: 344 348.
31. Mancia G, Giannattasio C, Seravalle G, Quarti-Trevano F, Grassi G (2009). Protective effects of renin-angiotensin blockade beyond blood pressure control. J Hum Hypertens 23: 570 577.
32. Marque V, Kieffer P, Atkinson J, Lartaud-Idjouadiene I (1999). Elastic properties and composition of the aortic wall in old spontaneously hypertensive rats. Hypertension 34: 415 422.
33. Mori T, Nishimura H, Ueyama M, Kubota J, Kawamura K (1995). Comparable effects of angiotensin II and converting enzyme blockade on hemodynamics and cardiac hypertrophy in spontaneously hypertensive rats. Jpn Circ J 59: 624 630.
34. Mulvany MJ, Baumbach GL, Aalkjaer C, Heagerty AM, Korsgaard N, Schiffrin EL et al. (1996). Vascular remodelling. Hypertension 28: 505 506.
35. Napoli C, Cicala C, D'Armiento FP, Roviezzo F, Somma P, de Nigris F et al. (1999). Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in watanabe heritable hyperlipidemic rabbits. Gen Pharmacol 33: 467 477. (Pubitemid 30047152)
36. de Nigris F, D'Armiento FP, Somma P, Casini A, Andreini I, Sarlo F et al. (2001). Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 81: 107 115.
37. Ohara Y, Peterson TE, Harrison DG (1993). Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91: 2546 2551.
38. Okunishi H, Kawamoto T, Kurobe Y, Oka Y, Ishii K, Tanaka T et al. (1991). Pathogenetic role of vascular angiotensin-converting enzyme in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol 18: 649 659.
39. Panza JA, García CE, Kilcoyne CM, Quyyumi AA, Cannon RO 3rd. (1995). Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 91: 1732 1738.
40. Pasini AF, Garbin U, Nava MC, Stranieri C, Pellegrini M, Boccioletti V et al. (2007). Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 20: 443 450.
41. Raasch W, Bartels T, Schwartz C, Häuser W, Rütten H, Dominiak P (2002). Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors? J Hypertens 20: 2495 2504.
42. Riganti C, Costamagna C, Bosia A, Ghigo D (2006). The NADPH oxidase inhibitor apocynin (acetovanillone) induces oxidative stress. Toxicol Appl Pharmacol 212: 179 187.
43. Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA (2001). Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 414: 71 78.
44. Schiffrin EL, Hayoz D (1997). How to assess vascular remodelling in small and medium-sized muscular arteries in humans. J Hypertens 15: 571 584.
45. Shiota N, Miyazaki M, Okunishi H (1992). Increase of angiotensin converting enzyme gene expression in the hypertensive aorta. Hypertension 20: 168 174.
46. Šimko F, Šimko J, Fábryová M (2003). ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle. Cardiovasc Drugs Ther 17: 287 290.
47. Subissi A, Evangelista S, Giachetti A (1999). Preclinical profile of Zofenopril: An angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev 17: 115 133.
48. Takai S, Jin D, Sakaguchi M, Miyazaki M (2004). Significant target organs for hypertension and cardiac hypertrophy by angiotensin-converting enzyme inhibitors. Hypertens Res 27: 213 219.
49. Tang EH, Vanhoutte PM (2009). Prostanoids and reactive oxygen species: team players in endothelium-dependent contractions. Pharmacol Ther 122: 140 149.
50. Van den Worm E, Beukelman CJ, Van den Berg AJ, Kroes BH, Labadie RP, Van Dijk H (2001). Effects of methoxylation of apocynin and analogs on the inhibition of reactive oxygen species production by stimulated human neutrophils. Eur J Pharmacol 433: 225 230.
51. Vejrazka M, Mícek R, Stípek S (2005). Apocynin inhibits NADPH oxidase in phagocytes but stimulates ROS production in non-phagocytic cells. Biochim Biophys Acta 1722: 143 147.
52. Webb RL, Abramson ML, Beil ME, Odorico LM, Chatelain RE (1997). Effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, CGS 30440, on blood pressure and cardiac hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol 30: 632 642.
53. Weir MR (2007). Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 29: 1803 1824.
54. Yang D, Félétou M, Boulanger CM, Wu HF, Levens N, Zhang JN et al. (2002). Oxygen-derived free radicals mediate endothelium-dependent contractions to acetylcholine in aortas from spontaneously hypertensive rats. Br J Pharmacol 136: 104 110.
55. Yang D, Félétou M, Levens N, Zhang JN, Vanhoutte PM (2003). A diffusible substance(s) mediates endothelium-dependent contractions in the aorta of SHR. Hypertension 41: 143 148.